Connect with us

Business

Mahindras overall auto sales touch 1,04,309 units in January, up by 24%

Published

on

Mahindras overall auto sales touch 1,04,309 units in January, up by 24%


Mumbai: Indian automobile manufacturer Mahindra & Mahindra Ltd. on Sunday said the company’s overall auto sales, including exports, stood at 1,04,309 vehicles in January 2026, surging 24 per cent year‑on‑year. Sports utility vehicle (SUV) domestic sales touched 63,510 units in January, up 25 per cent, while commercial vehicle domestic sales were 27,656 units, up 22 per cent, a company release said.

The total exports for January were 3,577 vehicles, up 5 per cent YoY, and while year‑to‑date exports in FY26 till January end stood at 33,638 vehicles, up 23 per cent, it added. The company also saw strong year‑to‑date performance across segments, with utility vehicles posting a 19 per cent rise in FY26 YTD passenger vehicle sales in January, while three‑wheelers jumped 28 per cent on a FY26 YTD basis.

Building on the strong momentum of last year’s performance, the company began the year on a strong note in January by achieving impressive SUV sales and total PV sales, said Nalinikanth Gollagunta, CEO, Automotive Division, M&M Ltd.

Add Zee News as a Preferred Source


“On January 14, we opened bookings for XUV7XO and XEV 9S, clocking 93,689 bookings for a booking value of Rs. 20,500 Crore – a record-breaking milestone in just 4 hours,” Gollagunta added.

Three‑wheeler sales, including electric models, rose 28 per cent YoY in January to 9,566 units, while YTD sales for FY26 surged 28 per cent to 92,012 units.

Sales of light commercial vehicles in the 2‑ton to 3.5‑tonne segment rose 23 per cent to 23,647 units in January, the release noted.

Mahindra & Mahindra capped off December 2025 with its highest-ever volumes in SUVs and light commercial vehicles.

The company sold 50,946 SUVs in the domestic market during the month, registering a 23 per cent growth, while total vehicle sales, including exports, stood at 86,090 units, marking a 25 per cent year-on-year increase.

Commercial vehicle sales also grew strongly, supported by sustained demand in the LCV segment. Mahindra said the strong finish to 2025 reflects growing customer confidence and the success of its SUV-led strategy.



Source link

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Business

Interest rate cuts not on the horizon, Bank of England governor says

Published

on

Interest rate cuts not on the horizon, Bank of England governor says



Reopening the Strait of Hormuz is “the best thing to do” to prevent interest rates rising, Bank of England governor Andrew Bailey has said.

In an interview on Thursday evening after the Bank’s Monetary Policy Committee (MPC) voted unanimously to leave the rate unchanged at 3.75%, Mr Bailey said any further cuts are “not on the horizon” as he hinted at possible hikes.

It is the first time that all members have voted the same way since September 2021.

Iran effectively closed the vital oil and gas shipping route after the US and Israel attacked the country, which has pushed up global prices.

Mr Bailey said the war in the Middle East is hitting petrol pumps now, will likely increase household energy costs in summer, and put pressure on food prices.

He told LBC’s Andrew Marr: “The duration of this problem is crucial.

“I would also say very clearly that the best way to solve this situation is not through monetary policy. It is through sorting out at the source of what’s going on.

“Frankly, reopening the Strait of Hormuz is the best thing to do. Get the energy market back on its normal footing, as it were.”

Asked if he has a message for US President Donald Trump, Israeli Prime Minister Benjamin Netanyahu, and “whoever’s in charge in Tehran”, Mr Bailey said: “The best thing we can do actually for the world economy… is to sort out the problem in terms of reopening the energy supply lines, because that is in the best interest of people in the world.”

UK military planners have joined the US Central Command to help formulate proposals for opening the Strait.

The MPC now expects Consumer Prices Index inflation to be around 3% in the second quarter of 2026, up from the 2.1% that had been forecast in February, with a potential rise in inflation up to 3.5% in the third quarter.

Mr Bailey was asked if he foresees, in the final two years of his term, the ambition to reduce inflation to at or below 2% being fulfilled.

He told the programme: “If you’d asked me this question three weeks ago, I was very optimistic on this.”

The governor added: “We are fully committed to the inflation target, and our job, frankly, is to deal with the shocks as they come along.

“I have to do that. I don’t wish them. I wish they were not happening, but they are and we will have to deal with them.”

He said the impact of the war will likely feed through into a higher Ofgem energy price cap from July.

It was put to Mr Bailey that the Middle East crisis comes at a time when the UK economy has already “not been growing strongly”.

He responded: “It is a very difficult time to have this happen, but frankly, any time would be pretty difficult to have this happen.

“This is a major shock to energy prices, and we have to deal with it.”

He said the “sustainable rate of growth” in the UK needs to be raised which could come from investment from pensions and artificial intelligence.

“I’m not starry-eyed about it, but it is probably the most likely area that we’re going to raise the growth rate of the economy and that’s important”, he said of AI.

The MPC signalled that if the conflict persists and has a bigger impact on UK prices, it would need to take a “more restrictive policy stance”, which indicates higher interest rates to control inflation.

The governor added: “The longer it goes on… I’m afraid to say, but it is rather an obvious point, the effect will be larger.”

He said that is why it is “imperative” that “everything is done that can be done to alleviate this effect”, adding: “That is the critical thing.”



Source link

Continue Reading

Business

Video: The Effects of High Oil Prices

Published

on

Video: The Effects of High Oil Prices


new video loaded: The Effects of High Oil Prices

Our chief economics correspondent, Ben Casselman, breaks down how gasoline prices have responded to the oil crisis in the Persian Gulf, and what is in store for inflation if the price of oil remains above $100 per barrel.

By Ben Casselman, Sutton Raphael, James Surdam, Joey Sendaydiego, Estelle Caswell and June Kim

March 19, 2026



Source link

Continue Reading

Business

FDA approves higher dose version of weight loss drug Wegovy as Novo Nordisk tries to win back market share

Published

on

FDA approves higher dose version of weight loss drug Wegovy as Novo Nordisk tries to win back market share


The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, Copenhagen, Denmark, Feb. 4, 2026.

Tom Little | Reuters

The Food and Drug Administration on Thursday approved a higher-dose version of Novo Nordisk‘s blockbuster weight loss injection Wegovy, as the company pushes to win back market share from chief rival Eli Lilly.

Novo expects to launch the higher, 7.2-milligram dose of Wegovy in April. The Danish drugmaker is positioning that version to better compete with Lilly’s obesity drug Zepbound, which has proven to be more effective at promoting weight loss than the standard, 2.4-milligram dose of Wegovy.

That higher efficacy has helped Zepbound become the preferred obesity medication among prescribers and patients, even though it entered the U.S. market later than Wegovy, and has solidified Lilly’s position as the dominant player in the space.

The high-dose Wegovy helped patients with obesity lose an average 20.7% of their weight after 72 weeks in a phase three trial. The standard dose of Wegovy has shown around 15% weight loss on average in clinical trials.

More CNBC health coverage

“I think it really makes it more competitive, and it really reduces the delta there,” Dr. Jason Brett, principal U.S. medical head at Novo Nordisk, said in an interview Thursday ahead of the approval.

“But even more importantly, I think it just gives patients another option if they’re not reaching their targets, and achieving some of these higher weight losses for certain patients,” he added.

In a separate phase three trial on patients with obesity and Type 2 diabetes, high-dose Wegovy demonstrated an average weight loss of 14.1%. People with diabetes typically have a harder time losing weight than people without the condition.

It marks the first approval of a GLP-1 treatment under the FDA’s new national priority voucher plan that aims to cut drug review times to one to two months for companies the agency says are supporting U.S. national health priorities. The FDA launched the pilot plan in June.

Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.



Source link

Continue Reading

Trending